- Home
- KPLT vs KYNB Comparison
KPLT vs KYNB Comparison
Compare KPLT & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KPLT | KYNB |
|---|---|---|
| Founded | 2012 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.7M | 31.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KPLT | KYNB |
|---|---|---|
| Price | $5.89 | $6.94 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 19.2K | ★ 39.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.42 | N/A |
| Revenue Next Year | $15.48 | N/A |
| P/E Ratio | ★ N/A | $0.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.50 | $6.76 |
| 52 Week High | $24.15 | $9.58 |
Technical Indicators
Market Signals| Indicator | KPLT | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 36.50 | 37.11 |
| Support Level | $5.50 | N/A |
| Resistance Level | $6.92 | $8.89 |
| Average True Range (ATR) | 0.34 | 0.52 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 18.13 | 9.69 |
Price Performance
Historical ComparisonAbout KPLT Katapult Holdings Inc.
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.
About KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.